US20020028798A1
(en)
*
|
1995-12-12 |
2002-03-07 |
Omeros Medical Systems |
Irrigation solution and method for inhibition of pain and inflammation
|
US7091181B2
(en)
|
1994-12-12 |
2006-08-15 |
Omeros Corporation |
Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
|
WO2000023072A1
(en)
*
|
1998-10-20 |
2000-04-27 |
Omeros Medical Systems, Inc. |
Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation
|
EP0934270A1
(en)
*
|
1996-05-30 |
1999-08-11 |
Merck & Co., Inc. |
A method of treating cancer
|
AU5610398A
(en)
|
1997-02-28 |
1998-09-18 |
Warner-Lambert Company |
Method of treating or preventing septic shock by administering a mek inhibitor
|
CA2281903A1
(en)
|
1997-03-28 |
1998-10-08 |
The Research Foundation Of State University Of New York |
Antisense oligonucleotides for mitogen-activated protein kinases as therapy for breast cancer
|
US6007991A
(en)
*
|
1997-03-28 |
1999-12-28 |
The Research Foundation Of Suny |
Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
|
CN1163475C
(zh)
*
|
1997-07-01 |
2004-08-25 |
沃尼尔·朗伯公司 |
4-溴或4-碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途
|
NZ501277A
(en)
*
|
1997-07-01 |
2002-12-20 |
Warner Lambert Co |
-2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
|
US6506798B1
(en)
|
1997-07-01 |
2003-01-14 |
Warner-Lambert Company |
4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
|
US6310060B1
(en)
|
1998-06-24 |
2001-10-30 |
Warner-Lambert Company |
2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
|
US6821963B2
(en)
|
1997-07-01 |
2004-11-23 |
Warner-Lambert Company |
4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
|
US6319955B1
(en)
|
1998-01-06 |
2001-11-20 |
The General Hospital Corporation |
Use of MEK1 inhibitors as protective agents against damage due to ischemia
|
AU1951499A
(en)
*
|
1998-01-06 |
1999-07-26 |
General Hospital Corporation, The |
Use of mek1 inhibitors as protective agents against damage due to ischemia
|
US6098631A
(en)
*
|
1998-01-21 |
2000-08-08 |
The Regents Of The University Of Michigan |
Compositions and methods for treating autoimmune disease
|
ES2268854T3
(es)
*
|
1998-03-24 |
2007-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibidores de la vascularizacion.
|
US20030219427A1
(en)
*
|
1998-08-18 |
2003-11-27 |
Allen Hamish J. |
TPL-2/COT kinase and methods of use
|
US6846799B1
(en)
|
1998-08-18 |
2005-01-25 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
US7354894B2
(en)
*
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
KR20010101203A
(ko)
*
|
1998-12-15 |
2001-11-14 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
Mek 저해제의 이식 조직 거부를 예방하기 위한 용도
|
EP1143957A3
(en)
*
|
1998-12-16 |
2002-02-27 |
Warner-Lambert Company |
Treatment of arthritis with mek inhibitors
|
DE69924641D1
(de)
*
|
1999-01-07 |
2005-05-12 |
Warner Lambert Company Llc Mor |
Behandlung von asthma anhand von mek-inhibitoren
|
CA2348236A1
(en)
*
|
1999-01-13 |
2000-07-20 |
Stephen Douglas Barrett |
4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
|
ES2252996T3
(es)
|
1999-01-13 |
2006-05-16 |
Warner-Lambert Company Llc |
Derivados de bencenosulfonamida y su uso como inhibidores de mek.
|
ATE302761T1
(de)
|
1999-01-13 |
2005-09-15 |
Warner Lambert Co |
1-heterozyklus-substituierte diarylaminen
|
ATE311363T1
(de)
*
|
1999-01-13 |
2005-12-15 |
Warner Lambert Co |
Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
|
DE69926800T2
(de)
|
1999-01-13 |
2006-05-18 |
Warner-Lambert Company Llc |
Benzoheterozyklen und ihre verwendung als mek inhibitoren
|
WO2000050030A1
(en)
*
|
1999-02-25 |
2000-08-31 |
Ted Ebendal |
New use
|
GB9920908D0
(en)
|
1999-09-03 |
1999-11-10 |
Indena Spa |
Chalcone coumarins
|
GB9920910D0
(en)
|
1999-09-03 |
1999-11-10 |
Indena Spa |
Novel chalcones
|
US7001905B2
(en)
*
|
2000-03-15 |
2006-02-21 |
Warner-Lambert Company |
Substituted diarylamines as MEK inhibitors
|
EP1365796A2
(en)
|
2000-09-01 |
2003-12-03 |
Van Andel Institute |
Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
|
WO2002069960A2
(en)
*
|
2001-03-06 |
2002-09-12 |
Axxima Pharmaceuticals Ag |
Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
|
US6806293B1
(en)
*
|
2001-03-12 |
2004-10-19 |
Darley Pharmaceuticals Ltd |
Use of pheromone compounds having MAP kinase modulating activity
|
WO2002072809A1
(en)
*
|
2001-03-12 |
2002-09-19 |
Alydar Pharmaceuticals, Inc. |
Screening non-peptide, non-steroid invertebrate pheromone compounds for mitogen-activated protein kinase modulating activity
|
CA2442015A1
(en)
*
|
2001-03-22 |
2002-10-03 |
Van Andel Institute |
Anthrax lethal factor inhibits tumor growth and angiogenesis
|
IL149462A0
(en)
*
|
2001-05-09 |
2002-11-10 |
Warner Lambert Co |
Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
|
KR20020096367A
(ko)
*
|
2001-06-19 |
2002-12-31 |
주식회사 티지 바이오텍 |
관절염 예방 또는 치료제 및 그것의 스크리닝 방법
|
KR20020096368A
(ko)
*
|
2001-06-19 |
2002-12-31 |
주식회사 티지 바이오텍 |
연골세포의 분화촉진, 연골세포의 탈분화 억제 또는탈분화된 연골세포의 재분화 촉진제, 그것의 스크리닝방법 및 그것을 이용한 연골세포의 제조방법
|
DOP2003000556A
(es)
*
|
2002-01-23 |
2003-10-31 |
Warner Lambert Co |
Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
|
MXPA04005527A
(es)
*
|
2002-01-23 |
2005-03-23 |
Warner Lambert Co |
ESTERES HIDROXIMATO DEL áCIDO N-(4-FENIL SUSTITUIDO)-ANTRANILICO.
|
EP1509614A4
(en)
*
|
2002-02-15 |
2007-09-12 |
Gen Hospital Corp |
MAP KINASE INHIBITORS FOR REGULATING TUMOR ASSOCIATED ANTIGENE EXPRESSION
|
PT3000810T
(pt)
*
|
2002-03-13 |
2017-10-25 |
Array Biopharma Inc |
Derivados de benzimidazole alquilado n3 como inibidores de mek
|
US7235537B2
(en)
*
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
UA76837C2
(uk)
*
|
2002-03-13 |
2006-09-15 |
Еррей Байофарма Інк. |
N3 алкіловані похідні бензімідазолу як інгібітори мек
|
CA2506320A1
(en)
*
|
2002-11-21 |
2004-06-10 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
|
DE602004020741D1
(de)
*
|
2003-02-26 |
2009-06-04 |
Kowa Co |
Mittel zur behandlung der allergischen kontaktdermatitis
|
US20050049276A1
(en)
*
|
2003-07-23 |
2005-03-03 |
Warner-Lambert Company, Llc |
Imidazopyridines and triazolopyridines
|
ATE442847T1
(de)
*
|
2003-07-24 |
2009-10-15 |
Warner Lambert Co |
Benzimidazol-derivate als mek-hemmer
|
US7144907B2
(en)
*
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
US7538120B2
(en)
*
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
US7517994B2
(en)
*
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
PT1682138E
(pt)
*
|
2003-11-19 |
2011-02-28 |
Array Biopharma Inc |
Inibidores heterocíclicos de mek
|
US7732616B2
(en)
*
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
WO2005051304A2
(en)
*
|
2003-11-21 |
2005-06-09 |
Array Biopharma Inc. |
Akt protein kinase inhibitors
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
AR051248A1
(es)
*
|
2004-10-20 |
2007-01-03 |
Applied Research Systems |
Derivados de 3-arilamino piridina
|
US20070293544A1
(en)
*
|
2004-11-24 |
2007-12-20 |
Ulrich Abel |
Novel 4-Arylamino Pyridone Derivatives as Mek Inhibitors for the Treatment of Hyper-Proliferative Disorders
|
EP1922307B1
(en)
|
2005-05-18 |
2011-12-28 |
Array Biopharma, Inc. |
Heterocyclic inhibitors of mek and methods of use thereof
|
US20080199449A1
(en)
*
|
2005-08-12 |
2008-08-21 |
The General Hospital Corporation |
Methods and Compositions for Use in Treating Vascular Diseases and Conditions
|
AU2006306991A1
(en)
|
2005-10-28 |
2007-05-03 |
Takeda Pharmaceutical Company Limited |
Heterocyclic amide compound and use thereof
|
CN103288753A
(zh)
|
2006-07-06 |
2013-09-11 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶
|
SI2054418T1
(sl)
|
2006-07-06 |
2012-02-29 |
Array Biopharma Inc |
Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
|
WO2008006025A1
(en)
|
2006-07-06 |
2008-01-10 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as akt protein kinase inhibitors
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
WO2009006567A2
(en)
|
2007-07-05 |
2009-01-08 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
US8377937B2
(en)
*
|
2007-07-05 |
2013-02-19 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
WO2009018320A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Limerick Biopharma, Inc. |
Pyrone analog compositions and methods
|
US20090062255A1
(en)
*
|
2007-08-17 |
2009-03-05 |
Thallion Pharmaceuticals Inc. |
Tumor-targeting evaluation methodology and compounds related thereto
|
AU2009204025B2
(en)
*
|
2008-01-09 |
2014-02-20 |
Array Biopharma Inc. |
Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
NZ586720A
(en)
*
|
2008-01-09 |
2012-11-30 |
Array Biopharma Inc |
Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
|
PL2307376T3
(pl)
*
|
2008-08-04 |
2016-04-29 |
Merck Patent Gmbh |
Nowe związki fenyloaminoizonikotynoamidowe
|
US8993630B2
(en)
|
2008-11-10 |
2015-03-31 |
Bayer Intellectual Property Gmbh |
Substituted sulphonamido phenoxybenzamides
|
EP2491016A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
CA2777071A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
KR20130113430A
(ko)
|
2010-08-05 |
2013-10-15 |
케이스 웨스턴 리저브 유니버시티 |
신경 연결의 발달 장애에 대한 erk 억제제
|
JP2013542214A
(ja)
|
2010-10-29 |
2013-11-21 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
置換フェノキシピリジン類
|
PT2694072T
(pt)
|
2011-04-01 |
2018-02-26 |
Genentech Inc |
Combinação de composto inibidor de akt e abiraterona para utilização em tratamentos terapêuticos
|
US9682082B2
(en)
|
2011-04-01 |
2017-06-20 |
Genentech, Inc. |
Combinations of AKT and MEK inhibitor compounds, and methods of use
|
US20140228418A1
(en)
*
|
2011-05-23 |
2014-08-14 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mek inhibitors
|
EP2714037B1
(en)
|
2011-05-25 |
2016-07-13 |
Université Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
CA2853799A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
AU2012332424A1
(en)
|
2011-11-02 |
2014-06-05 |
Synta Pharmaceuticals Corp. |
Combination therapy of Hsp90 inhibitors with platinum-containing agents
|
JP2014533299A
(ja)
|
2011-11-14 |
2014-12-11 |
シンタ ファーマシューティカルズ コーポレーション |
Braf阻害剤とhsp90阻害剤の組合せ療法
|
US20140242595A1
(en)
|
2013-02-22 |
2014-08-28 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
WO2015038704A1
(en)
|
2013-09-11 |
2015-03-19 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Compositions for preparing cardiomyocytes
|
WO2015164228A1
(en)
|
2014-04-21 |
2015-10-29 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
US20170248603A1
(en)
|
2014-10-06 |
2017-08-31 |
Dana-Farber Cancer Institute, Inc. |
Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
EP3579872A1
(en)
|
2017-02-10 |
2019-12-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
WO2020051370A1
(en)
*
|
2018-09-06 |
2020-03-12 |
North Carolina Central University |
Discovery of novel potent inhibitors of the map3k mekk2
|
EP4025215A1
(en)
|
2019-09-02 |
2022-07-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of pyrvinium for the treatment of a ras pathway mutated acute myeloid leukemia
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|